ARGUS/OVERWATCH
LATEST VERSION
DEVELOPING · 23 OCT → 31 OCT 2026 · 9 EDITIONS · 34 OUTLETS

Personalised mRNA vaccine reduces melanoma recurrence risk in phase 3 trial

How this story moved: how many newsrooms carried it at each run, when each one picked it up, how our summary's headline changed, and which figures and names held from the first reports to the latest. Everything here is counted from the coverage; none of it is a judgement of anyone's motives.

OUTLETS CARRYING THE STORY, RUN BY RUN

0 17 34 24 Oct 25 Oct 26 Oct 27 Oct 28 Oct 29 Oct 30 Oct 31 Oct 23 Oct 14:30 UTC · Personalised mRNA vaccine reduced melanoma recurrence risk in phase 3 trial 23 Oct 18:16 UTC · Personalised mRNA vaccine reduced melanoma recurrence risk in phase 3 trial 24 Oct 00:12 UTC · Personalised mRNA vaccine reduces melanoma recurrence risk in phase 3 trial 24 Oct 06:13 UTC · Personalised mRNA vaccine reduces melanoma recurrence risk in phase 3 trial

HOW OUR HEADLINE CHANGED · 2 HEADLINES

  1. 23 Oct, 14:30 UTC

    Personalised mRNA vaccine reduced melanoma recurrence risk in phase 3 trial

  2. 24 Oct, 00:12 UTC

    Personalised mRNA vaccine reduces melanoma recurrence risk in phase 3 trial

WHAT HELD, WHAT CAME LATER

From the first reports to the latest

  • Nothing ran from the first third of the coverage to the last.

Entered the story later

  • Nothing new took hold after the first third.